Yang H, et al. - By analyzing 27 relevant studies with 1,048 participants, researchers further assessed the efficacy as well as the safety of direct acting antiviral (DAA) -based therapies in hepatitis C virus infected patients exhibiting renal function impairment. The included studies were identified from MEDLINE, EMBASE, and the Cochrane Library. At the close of the treatment or 4, 12, 24 weeks following treatment, the pooled virologic response rates were reported to be 97.0%, 80.9%, 94.1%, and 89.6%, respectively. The pooled relapse rate was estimated to be 6.4%. For adverse events and severe adverse events resulting in discontinuation, the pooled incidence was 47.6% and 2.9%, respectively. In this patient group, DAA-based treatments were found to be efficacious as well as safe.